Introduction
The liver performs hundreds of critical functions to maintain homeostasis and health. These functions include production of serum proteins and hormones, detoxification of foreign and naturally occurring chemicals, glucose and lipid metabolism and so on. It is therefore foreseeable that liver diseases severely affect health and can be life threatening. There are four major types of liver disease, cirrhosis, fatty liver, hepatitis and liver cancer, with the latter two being among the most serious global public health problems (Osada et al., 2004) .
Hepatitis means 'inflammation of the liver' in Latin, and the most common etiologies are infections by one of five viruses, called hepatitis A, B, C, D and E (Hu, 2008) . All of these viruses can cause acute disease with symptoms lasting several weeks, including yellowish skin and eyes (jaundice), dark urine, extreme fatigue, nausea, vomiting and abdominal pain. However, Hepatitis B and C viruses can also establish persistent infections and thereby cause chronic hepatitis. According to WHO statistics, more than 2 billion people alive today have been infected with hepatitis B virus (HBV) at some time in their lives, and of these, about 350 million remain chronically infected and are carriers of the virus. The WHO estimates that about 180 million people, 3% of the world's population, are infected with Hepatitis C virus (HCV), 130 million of whom are chronic HCV carriers at risk of developing liver cirrhosis and/or liver cancer (Farinati et al., 2007) . It is estimated that three to four million people are newly infected each year, with 70% of them developing chronic hepatitis. Both HBV and HCV chronically infected individuals are at high risk of death from cirrhosis of the liver and liver cancer, diseases that kill about one million people each year (Wiegand et al., 2008) . Among all risk factors, HCV is responsible for 50-75% of all liver cancer cases, and two thirds of all liver transplants in the developed world (Mukherjee and Sorrell, 2008) . China is the country with one of the highest HBV infection rates and a very high incidence of hepatocellular carcinoma (HCC). Based on statistics from the Chinese National Center of Disease Control and Prevention about 9.2% of the Chinese population (0.12 billion) is HBV positive, and among these individuals, about 30 million people have chronic infections. Interestingly, the occurrence of HCC in males is about nine times higher than it is in females.
Hepatocellular carcinoma is the most common form of liver cancer arising from hepatocytes, the major cell type of the liver. Currently, HCC is estimated to be the third leading cause of cancer death worldwide (Wong and Ng, 2008) . It is especially prevalent in parts of Asia and Africa. About 80% of people with HCC have cirrhosis, which is the most severe form of liver fibrosis, the end point of chronic liver damage (Hemming et al., 2001) . In addition to preventing new HBV and HCV infections, approaches to HCC prevention should focus on the molecular regulators of a disease process termed the inflammation-fibrosis-cancer axis.
There are many regulators involved in the inflammation-fibrosis-cancer process, and the NF-kB (nuclear factor-kappa B) signaling pathway appears to have a central function in liver homeostasis, pathophysiology and regulation of the inflammation-fibrosis-cancer axis. Since its discovery in 1986, NF-kB has received much attention, because of its activation by many different stimuli and its diverse, yet prominent, roles in maintaining tissue homeostasis, control of disease development, regulation of cell survival and activation of innate and adaptive immune responses. The term NF-kB refers to a family of inducible dimeric transcription factors that recognize a common sequence motif, the kB site. There are seven structurally related NF-kB polypeptides in mammals: NF-kB1:p105 and p50, NF-kB2:p100 and p52, RelA(p65), c-Rel and RelB, which can form large numbers of homo-and heterodimers (Ghosh and Karin, 2002; Hayden et al., 2006) . The most common form is the p50:RelA heterodimer. Studies using knockout mice revealed that most NF-kB family members are dispensable for embryonic development with the exception of RelA, whose absence results in mid-embryonic lethality because of extensive liver apoptosis (Beg et al., 1995) , results that provided the first evidence for the important function of NF-kB in liver physiology. Most NF-kB family members, including RelA are involved in innate and adaptive immune responses and lymphoid organ development (Bonizzi and Karin, 2004; Gerondakis et al., 2006) . At the cellular level NF-kB activation is important for inhibition of programmed and elicited cell death and maintenance of cell survival (Lin and Karin, 2003) . The survival functions of NF-kB are accomplished through induction of critical genes encoding antiapoptotic proteins, such as Bcl-X L , c-FLIP, A1/Bfl-1 and others (Lin and Karin, 2003) ( Figure 1 ). NF-kB also controls the expression of antioxidant genes that contribute to its prosurvival function including ferritin heavy chain (Pham et al., 2004) and superoxide disimutase 2 (SOD2) . Another NF-kB target gene that contributes to both survival and innate immune functions is the Hif-1a gene, encoding the oxygen-regulated subunit of the hypoxia responsive transcription factor HIF-1 (Rius et al., 2008) .
Two major pathways, the classical or canonical, of NF-kB activation have been identified (Figure 2 ). The canonical pathway depends on the inducible degradation of inhibitory IkB proteins, which retain most NFkB dimers (except those that contain RelB) in the cytoplasm (Ghosh and Karin, 2002) . The alternative pathway is based on the inducible processing of NFkB2/p100 to its N-terminal p52 portion, and as p100 is mainly associated with RelB in the cytoplasm, activation of this pathway leads to specific activation of p52:RelB Figure 1 Crosstalking between apoptosis and nuclear factorkappa B (NF-kB) signaling. A wide range of different stimuli can induce apoptosis, including activation of cell death receptors (CD95, TRAIL-R1 þ 2,TNFR1), ionizing radiation, growth factor deprivation and chemotherapeutic drugs. Indeed, NF-kB can be correspondingly activated by the molecule within these apoptosis signaling. Meanwhile, the antiapoptotic effect can be carried out by NF-kB targeting genes including Bcl-2 family, TRAF2, CIAP, FLIP and A-20, which has antiapoptosis effect by either reactivating NF-kB signaling or blocking signal transduction as a negative feedback to activation of apoptosis. Here, we roughly demonstrated some crucial apoptosis signaling pathways and the crosstalk with NF-kB signaling.
Figure 2 Nuclear factor-kappa B (NF-kB) activation signaling pathway. The canonical pathway and the alternative pathway are included. The canonical pathway is triggered by microbial and viral infection and pro-inflammatory cytokines, this pathway is most essential in inflammatory reaction. p50:RelA complex which was defined as the final transcription factor of classical pathway will be released by phosphorylated Ik-B and translocated into nucleus to initiate gene transcription. The alternative pathway is triggered by certain members of the tumor necrosis factor (TNF) cytokine family that cause selective activation of p52:RelB dimers by inducing processing of the NF-kB2/p100 precursor protein, which mostly occurs as a heterodimer with RelB in the cytoplasm. Here, we have proposed Rank-mediated signaling pathway as another NF-kB activation signaling pathway to promote tumor growth and metastasis.
dimers (Ghosh and Karin, 2002) . Activation of the canonical pathway depends on the multi-subunit IkB kinase complex consisting of IKKa, IKKb and IKKg (DiDonato et al., 1997; Rothwarf and Karin, 1999) . In most cell types, it is the IKKb subunit that is directly responsible for IkB phosphorylation, whereas IKKg (NEMO) serves as the regulatory subunit, being essential for IKKb activation (Ghosh and Karin, 2002) . IKK activity is rapidly increased upon exposure to pro-inflammatory stimuli, such as tumor necrosis factor a (TNFa), interleukin (IL)-1 and lipopolysaccharide (LPS). Importantly, one of the target genes activated by canonical NF-kB pathway encodes IkBa (Sun et al., 1993) . Newly synthesized IkBa can enter the nucleus, remove NF-kB from DNA, and export the complex back to the cytoplasm to restore the original latent state (Ghosh and Karin, 2002) . Several other negative regulators of NF-kB activation, such as A20 (Coornaert et al., 2008) , have also been defined, but an extensive discussion of their mechanism of action and function is beyond the scope of this review.
Unlike the canonical pathway which is activated by many stimuli, the alternative pathway is activated only in response to a limited number of TNF family members including BAFF, CD40 ligand (CD40L), lymphotoxin a,b heterotrimers and RANK ligand (RANKL). Activation of the alternative pathway does not depend on IKKb or IKKg, but requires IKKa homodimers that directly phosphorylate p100 at C-terminal sites (Senftleben et al., 2001) and thereby induce the polyubiquitination of its C-terminal domain and lead to its limited proteasome-dependant proteolysis (Bonizzi and Karin, 2004) . Once the C-terminal portion of p100 is degraded, its N-terminal p52 portion which is bound to RelB translocates to the nucleus (Bonizzi and Karin, 2004) . The genes that are induced by p52:RelB and thus the alternative pathway are different from those that are regulated by the canonical pathway (Bonizzi and Karin, 2004) . Importantly, the major survival function of NF-kB is mostly mediated by the canonical pathway and its target genes and thus the pronounced features of both IKKb-and IKKg-deficient mice is midembryonic lethality because of extensive liver apoptosis (Li et al., 1999b; Makris et al., 2000) , a phenotype that is identical to that of RelA-deficient mice (Beg et al., 1995) .
Role of NF-jB in liver development and survival NF-kB has an important role in liver physiology and function. The hepatoprotective role of NF-kB was first observed upon RelA deletion (Beg et al., 1995) , and it is now clear that NF-kB protects the liver from TNFainduced apoptosis (Ghosh and Karin, 2002) . RelA-, IKKb-and IKKg-knockout mice die around embryonic days 12.5-14.5 because of increased TNFa-induced hepatocyte apoptosis (Beg et al., 1995; Li et al., 1999a; Makris et al., 2000; Rudolph et al., 2000) . In contrast, IKKa knockout mice survive until birth (Hu et al., 1999; Takeda et al., 1999) , suggesting that IKKa is not required for protection from TNFa-induced liver apoptosis. TNFa does not induce the killing of normal hepatocytes in vivo because of its ability to activate cytoprotective genes dependent on NF-kB. In addition to antiapoptotic molecules, such as c-FLIP , these cytoprotective molecules include the antioxidants ferritin heavy chain (Pham et al., 2004) , and SOD2 . Correspondingly, mice that cannot activate NF-kB in their liver exhibit excessive accumulation of reactive oxygen species upon challenge with hepatic toxins such as diethyl nitrosamine (DEN) .
To further assess the role of NF-kB in liver physiology and disease, two different mouse models with a hepatocyte-specific deletion of IKKb were created. Surprisingly, administration of soluble TNFa or LPS to either of them was insufficient to induce considerable hepatic apoptosis (Maeda et al., 2003 Luedde et al., 2005) . Furthermore, IKKb-deficient hepatocytes are not much more sensitive to TNFa in vitro than normal hepatocytes (Maeda et al., 2003) . However, mice with a hepatocyte-specific knockout of IKKg/NEMO are much more sensitive to hepatocyte apoptosis induced by administration of soluble TNFa (Luedde et al., 2005) . As previously shown in other cell types (Makris et al., 2000) , the deletion of IKKg results in complete inhibition of NF-kB activation, whereas deletion of IKKb results in residual NF-kB activation because of the presence of IKKa (Maeda et al., 2003) . Nonetheless, mice lacking hepatocyte IKKb are very sensitive to induction of liver damage upon administration of concanavalin A (ConA) (Maeda et al., 2003) . Administration of ConA induces a T cell-mediated hepatitis, which is analogous to HCV-or HBV-induced fulminant hepatitis. In the ConA model, infiltrating T lymphocytes express high amounts of membranebound TNFa, which leads to stronger and more prolonged activation of Jun kinase (JNK)1 than soluble TNFa, resulting in the death of IKKb-deficient hepatocytes (Maeda et al., 2003) . By contrast, JNK1-deficient mice are resistant to ConA-induced liver failure . Subsequent investigation revealed that one of the most critical factors for prevention of TNFa-induced hepatocyte death is the antiapoptotic protein c-FLIP, the transcription of whose gene is driven by NF-kB, but whose degradation is induced by JNK1 through the JNK1-activated ubiquitin ligase Itch . Thus, NF-kB promotes hepatocyte survival and liver integrity by keeping c-FLIP levels high, whereas JNK1 promotes hepatocyte death by decreasing c-FLIP expression.
The main physiological function of TNFa in the liver is not the induction of apoptosis, as normal hepatocytes do not die in response to soluble TNFa. In fact, TNFa may stimulate hepatocytes proliferation and liver regeneration, but these responses do not depend on NF-kB (Chaisson et al., 2002) . TNFa is also protective in the case of liver ischemia/reperfusion (I/R). When NF-kB signaling was blocked by transgenic expression of IkBa super-repressor, the liver was found to be very sensitive to reperfusion injury (Suetsugu et al., 2005) . Recent results indicated that hepatocyte-specific IKKbdeleted mice are resistant to hepatic I/R injury. Moreover, pharmacological inhibitors of IKKb were found effective in preventing hepatic I/R injury (Luedde et al., 2005) . Unlike the situation in intestinal I/R, where deletion of IKKb in epithelial cells increased the injury (Chen et al., 2003) , strong IKK activation is not seen after hepatic I/R (Uchinami et al., 2002) . Curiously, NF-kB activation in response to liver I/R is not mediated by the classical IKKb-dependent pathway, and instead depends on tyrosine phosphorylation of IkBa by Src family members (Fan et al., 2004) .
Several other kinases including glycogen synthase kinase (GSK)-3b and TANK-binding kinase 1/NF-kBactivating kinase (TBK1/NAK) are also involved in TNFa-induced NF-kB activation in hepatocytes through unknown mechanisms and mice lacking these kinases die during embryonic development just like IKKb-deficient mice, because of TNFa-induced apoptosis (Bonnard et al., 2000; Hoeflich et al., 2000; Schwabe et al., 2003) . However, the mechanisms by which these kinases contribute to NF-kB activity, especially in liver, are far from being understood. Most likely, these kinases affect NF-kB transcriptional activity rather than being involved in the degradation of IkB and induction of NF-kB DNA-binding activity. Moreover, it should not be overlooked that there is an ever-increasing evidence for NF-kB-independent activities of IKKa, IKKb and IKKg/NEMO, as well as the IkBs (Scheidereit, 2006) , and these may also contribute to some of the liver phenotypes mentioned above.
NF-kB operates in liver cells in the context of viral, metabolic, alcoholic and immune-driven stress, and its activation can lead to acute inflammatory as well as wound-healing responses. When the injury is iterative or chronic, activation of NF-kB is associated with persistently elevated expression of proinflammatory cytokines, chemokines and matrix metalloproteinases, which can eventually lead to fibrosis and cirrhosis, which may increase the risk of progression to HCC (Elsharkawy and Mann, 2007) . Studies in experimental models have shown that the NF-kB activation response in the liver is significantly influenced by sex, age and lipid content (Pikarsky et al., 2004; Zhao et al., 2005; Lawrence et al., 2007) . Studies on hepatic NF-kB in diseased human liver are rare. However, elevated hepatic NF-kB activity in alcoholic liver disease, and its correlation with the degree of inflammation and fibrosis have been reported (Ribeiro et al., 2004) .
Pathogen-associated molecular patterns (PAMPs) activate toll-like receptors (TLRs). TLR4 activation and signaling through the adapter protein MyD88 were recently shown to play an important role in the induction of liver fibrosis (Seki et al., 2007) . The PAMP responsible for TLR4 activation in this case appeared to be LPS, reaching the liver from the alcohol-injured colon through the portal vein. Receptor-recruited MyD88 recruits the ubiquitin ligase TRAF6 to activate the IKK complex through an induced proximity mechanism and thereby induce NF-kB nuclear translocation (Hacker and Karin, 2006) . The NF-kB target genes, which contribute to fibrosis remain to be identified, but one possible mediator could be IL-6 (Kayano and Okita, 2000; Bataller and Brenner, 2005) . As discussed below, IL-6 also has an important function in hepatocarcinogenesis.
Future work should focus on the possible involvement of NF-kB in human liver disease. In this respect it will be important to correlate the activation state of NF-kB with disease occurrence and progression. It will also be important to identify the cell type in the liver in which NF-kB is activated, as its function appears to be quite different in hepatocytes, Kupffer cells and hepatic myofibroblasts .
Helicobacter liver infection and NF-jB signaling
During the last two decades, research on the Helicobacter genus has focused on Helicobacter pylori-associated diseases such as chronic gastritis, peptic ulceration, gastric cancer and mucosa-associated lymphoid tissue lymphoma (Parsonnet et al., 1991 (Parsonnet et al., , 1994 Hopkins et al., 1996; Maaroos et al., 1999; Uemura et al., 2001) . However, other bacteria belonging to the Helicobacter genus have also been identified in the intestinal tracts and livers of humans and other mammals (Andersen, 2001; Solnick and Schauer, 2001) . The number of entero-hepatic Helicobacter spp. reported thus far is on the rise with H. pullorum, H. bilis, H. hepaticus, H. cinaedi, H. canis, H. rappini and H. rodentium all having been implicated in the pathogenesis of hepatobiliary disease.
Helicobacter pullorum can be transmitted in the feces of asymptomatic poultry and was first isolated from livers and intestinal contents of laying hens with vibrionic hepatitis (Stanley et al., 1994; Atabay et al., 1998) . Helicobacter bilis was first identified in inbred mice with chronic hepatitis (Fox et al., 1995) . Sequencing PCR-amplified 16S rRNA gene fragments, DNA from H. bilis was also detected in the gall bladders of five out of eight Chileans with chronic cholecystitis. In 1992, Helicobacter hepaticus was isolated from A/JCr mice suffering from HCC (Fox et al., 1994; Ward et al., 1994b) . Many patients infected with HBV or HCV eventually develop cirrhosis and HCC, but the possible role of bacterial coinfection, particularly of Heliocobacter spp. in the progression from viral hepatitis to HCC should not be ignored. Bile-tolerant Helicobacter spp. has been reported to produce a cytolethal distending toxin, which causes progressive cell enlargement and eventual cell death in cultured cells (Ward et al., 1994a; Young et al., 2000a, b) . In addition, it is now evident that in primates certain Helicobacter spp. induce liver, bile tract and pancreatic diseases (Fox et al., 1995) . Recent research has revealed that the presence of intracellular H. pylori within hepatocytes can increase DNA fragmentation. H. pylori infection of mice resulted in strain-species-dependent effects on hepatocytes, and a virulent strain caused cell cycle arrest and apoptosis of infected hepatocytes (Ito et al., 2008) .
The best characterized H. pylori virulence factor is the cag pathogenicity island, a 40 kb chromosomal DNA, which contains approximately 31 genes (Tomb et al., 1997; Alm et al., 1999) . Several of the genes present on the cag pathogenicity island encode components of a type IV secretion system, which allows the product of cytotoxin-associated gene A, a 120-130 kDa protein and other bacterial proteins encoded by the cag pathogenicity island to be injected into epithelial cells (Zarrilli et al., 1999; Ishikawa et al., 2008) . Cytotoxin-associated gene A is phosphorylated and binds to a tyrosine phosphatase, which induces secretion of IL-8, a potent chemotactic and activating factor for neutrophils, through the activation of NF-kB (Zarrilli et al., 1999) . The cag pathogenicity island also induces cell surface remodeling including the induction of pedestal formation, activation of the transcription factor AP-1 and expression of the AP-1 components c-Fos and c-Jun through activation of MAP kinases (Stein et al., 2000; Suerbaum et al., 2002) . Besides cytotoxin-associated gene A , LPS-a component of the outer membrane of Gram-negative bacteria, including H. pylori, leads to TLR4 activation and is therefore the main source of inflammation in Gram-negative infections (Kiechl et al., 2002) . As mentioned above, LPS binding to TLR4 activates signal transduction through MyD88, IRAK1 and TRAF6, culminating in the activation of NF-kB and MAP kinases (Hoshino et al., 1999; Kawai et al., 1999 Kawai et al., , 2001 ). This pathway leads to the synthesis and release of inflammatory cytokines such as IL-1, IL-8, TNF-a and various chemokines such as GROa, IP10, MIG and MIP-1a and -b (Gasperini et al., 1999) , inducible NO synthase (iNOS) (Alderton et al., 2001; Bogdan, 2001) , and antimicrobial peptides providing a critical link to the adaptive immune system (Benelli et al., 2002; Renshaw et al., 2002) . Induction of inflammation is an important component in the defense against H. pylori. Chronic H. pylori infection also results in the release of mutagenic substances such as iNOS metabolites which can induce oncogenic mutations (Mannick et al., 1996) . NO generated by iNOS is converted to reactive nitrogen species, which can exert oncogenic effects including direct DNA damage, oncogenic mutations, inhibition of apoptosis and may also promote angiogenesis (Jaiswal et al., 2001) . H. pylori infection is also known to induce the expression of the proinflammatory cyclooxygenase 2 (COX-2) enzyme (Salvemini et al., 1993; Ristimaki et al., 1997; Sung et al., 2000) . COX-2 expression is usually undetectable in most normal tissues, but is induced rapidly during an inflammatory reaction (Smith et al., 1996; Turini and DuBois, 2002) . COX-2 activity is induced by a variety of mediators including inflammatory cytokines such as TNFa, interferon-g and IL-1 (Williams et al., 1997) . COX-2 facilitates tumor growth by inhibiting apoptosis, maintaining cell proliferation and stimulating angiogenesis (Tsujii et al., 1997; Dubois et al., 1998) .
Research concentrating on Helicobacter infection of the liver is scarce. Only a few reports confirmed that H. pylori and other Helicobacter genus could infect the liver. Recently, however, Fox and colleagues have developed a model in H. hepaticus infection that can induce HCC in mice (Rogers et al., 2007) .
HBV and HCV infections and NF-jB signaling NF-kB can be activated in both structural and nonstructural proteins of hepatitis B and C viruses such as HBs antigen , HBc antigen (Cooper et al., 2005) , HBx antigen (Yun et al., 2002) and HCV non-structural and HCV core proteins (Mann et al., 2006) . During hepatitis virus infections the NF-kB signaling pathway is maintained in an activated state through induction of inflammatory mediators, such as TNFa.
Among all of the HBV-encoded proteins, HBx is the most harmful to the host. It is a multifunctional regulator of cellular signal transduction and a potent activator of NF-kB. HBx activates NF-kB by acting on two distinct NF-kB inhibitors IkBa and p105, the precursor for p50 (Su and Schneider, 1996; Weil et al., 1999) . HBx directly interacts with IkBa through amino acids 249-253 in the C-terminal domain of the sixth ankyrin repeat of IkBa, leading to accumulation of IkBa-HBx complexes and translocation of NF-kB into the nucleus. HBx also induces a dramatic reduction in the cytoplasmic concentration of p105, which also functions as an NF-kB inhibitor, resulting in the release and nuclear accumulation of RelA-containing NF-kB dimers. By contrast, HBx induces only a slight reduction in the cytoplasmic concentration of NF-kB2/p100 (Weil et al., 1999) . Another HBV antigen, which is very critical in liver infection is the surface antigen, PreS2, which binds to PKCa and PKCb to trigger a PKC-dependent activation of the c-Raf-1/MAP kinase signal transduction cascade, resulting in activation of transcription factors, such as AP-1 and NF-kB. By activation of this signaling cascade, PreS2 can stimulate hepatocyte proliferation (Hildt and Hofschneider, 1998) . Curiously, PreS2 can also downregulate the host immune response and inhibit LPS-induced COX-2 expression and IL-18 production by interfering with NF-kB activation in human macrophage cell lines (Claudio et al., 2002) .
Hepatitis C is a devastating disease worldwide. Proteins encoded by the etiologic agent, HCV, are believed to play important roles in HCV-associated pathogenesis. There are two different mechanisms of NF-kB activation by HCV. One is induced by HCV core protein which can bind to the death domain of TNF receptor 1 (TNFR1) and to the cytoplasmic domain of the LTb receptor (LTbR) to activate NF-kB (Tai et al., 2000; Sato et al., 2006) . HCV can also promote proliferation of human hepatoma cells by activation of the ERK MAP kinase pathway through upregulation of TGFa transcription through activation of NF-kB. Like HBV, HCV also infects immune cells, including macrophages and its core protein was found to suppress IKK activity such that NF-kB signaling is inhibited (Joo et al., 2005) . The second pathway leading to NF-kB activation depends on non-structural protein 5A (NS5A) which induces endoplasmic reticulum (ER) stress to cause NF-kB activation through tyrosine phosphorylation of IkBa, mediated by the tyrosine kinase ZAP-70 . Through its effects on ZAP-70 the NS5A protein has a critical role in the initiation of T-cell signaling. Among patients with chronic HCV infection, including those who respond to interferon therapy, it is those that produce anti-HBc antibodies who are more likely to develop HCC, than those without anti-HBc (Tanaka et al., 2006) . Viral hepatitis involves continuous interaction between the virus and the NF-kB-signaling system. Furthermore, some components of NF-kB signaling are necessary for virus replication . In addition, a host response based on virus-mediated activation of NF-kB and JAK-STAT signaling is required for induction of an immune and inflammatory response. The course and the final outcome of viral hepatitis are determined by the interaction between the liver and the virus.
The first-line antiviral host defense response entails the release of interferon and other cytokines into the bloodstream or intercellular fluid by virally infected cells, causing healthy cells to produce enzymes and other factors that counter the infection. Production of antiviral cytokines is NF-kB-dependent . Interferon-g is also dependent on the basal level of NF-kB, which is maintained by constitutively expressed IL-1a (Hurgin et al., 2007) . In addition, NFkB-induced TNFa and IL-1b can further augment the antiviral response . The immune response to hepatitis viruses is mainly regulated by NFkB-and interferon-signaling pathways Hiscott et al., 2003; Malmgaard, 2004) . After viral infection, NF-kB, IRF-3 or both, are activated and execute antiviral effects by activating the JAK-STAT pathway (Maher et al., 2007) . Although the inflammatory response triggered by viral infection contributes to the pathogenesis of acute and chronic hepatitis, it should not be forgotten that inflammation is a protective response, which in addition to countering viral replication is responsible for repairing the tissue damaged by the virus. However, in the liver this repair response can lead to replication of otherwise quiescent hepatocytes, some of which may harbor oncogenic mutations. As discussed below, this compensatory proliferative response is a major contributor to hepatocarcinogenesis.
NF-jB signaling and acute hepatitis
The term hepatitis refers to any inflammatory response of the liver. The most common etiology of acute hepatitis is infection with either hepatitis A, B or C viruses. Viral hepatitis occurs less commonly in response to infections with Epstein-Barr virus, cytomegalovirus, adenovirus, herpes simplex and Coxsackie virus. Virally produced PAMPs and viral proteins can be recognized by different TLRs and other innate immune receptors that lead to activation of NF-kB, AP-1 and IRFs (Crispe, 2003; Schwabe et al., 2006; Gao et al., 2008) . In a healthy liver, TLR signaling is in a state of 'liver tolerance', which is important for avoiding activation by the low levels of LPS to which the liver is continuously exposed as a result of its important role in detoxification of LPS that reaches the liver through the portal circulation (Seki et al., 2007) . If this tolerance is broken, hepatitis will ensue.
Survival effects of NF-kB in acute hepatitis
The plant lectin ConA is widely used to study acute hepatitis in mice as ConA-mediated hepatitis can simulate several aspects of viral and autoimmune hepatitis in humans including NK, NKT and T cell activation and production of inflammatory cytokines (Tiegs et al., 1992) . During ConA-mediated hepatitis, the production of factors TNFa and IL-6 is dramatically increased in response to NF-kB activation in T cells (Lazarus et al., 1997) . ConA stimulated T cells express membrane-bound TNFa which is a potent activator of both TNFR1 and TNFR2, leading to activation of both JNK and IKK signaling (Maeda et al., 2003) . Importantly, JNK activity is negatively regulated by NF-kB, such that IKKb delection in hepatocytes results in sustained JNK activation and increased JNK-induced cell death after ConA injection (Maeda et al., 2003) . Subsequent studies revealed that the proapoptotic activity of JNK is mediated mainly by JNK1 which activates the ubiquitin ligase Itch to induce c-FLIP degradation . The protective role of NF-kB in adult liver was confirmed in the ConA hepatitis model (Maeda et al., 2003) , and shown to involve inhibition of both apoptosis and necrosis . Some clinical cases support the antiapoptotic activity associated with NF-kB inhibitor because of diminished activation by expression of RelA/ p65 caused by hepatitis virus infection (Prusty et al., 2007) .
As mentioned above, NF-kB exerts its pro-survival effects through several mechanisms. In hepatocytes the most critical antiapoptotic protein induced by NF-kB appears c-FLIP (Chang et al., 2007) . FLIP inhibits apoptosis by interfering with caspase-8 activation (Micheau and Tschopp, 2003) . In addition, NF-kB prevents the accumulation of reactive oxygen species, which contribute to the induction of both apoptotis and necrosis through induction of genes encoding antioxidants such as SOD2 and ferritin heavy chain (Pham et al., 2004; Kamata et al., 2005) . Another important mechanism is the downregulation of JNK activation, but this is mediated through induction of the above mentioned antioxidants . The interaction between JNK and NF-kB signaling also controls liver regeneration or compensatory hepatocyte proliferation (Yamada et al., 1997; Schwabe et al., 2003; Sakurai et al., 2006) . NF-kB is a critical activator of innate immune responses which are initiated within epithelial or stromal cells of the infected tissue, as well as resident immune cells such as mast cells, DCs or Kupffer cells in the liver. Activation of NF-kB within such cells leads to expression of cytokines and chemokines that recruit additional effector cells such as neutrophils and other leukocytes, resulting in a characteristic inflammatory response. It was recently shown that IL-1a production by necrotic hepatocytes can trigger an inflammatory response involving IL-6 induction (Sakurai et al., 2008) and recruitment of neutrophils that can cause severe liver damage (Chen et al., 2007) . Therefore much of the tissue damage seen in acute hepatitis could be because of neutrophil infiltration. Importantly, NF-kB may also have an anti-inflammatory role which is provided by its ability to prevent necrosis and IL-1a release (Sakurai et al., 2008) . In addition, NF-kB activation was shown to suppress the production of IL-1b, the other isoform of the pro-inflammatory cytokine IL-1 (Greten et al., 2007) .
NF-jB in chronic hepatitis
Chronic hepatitis, although much less common than acute hepatitis, can persist for years, even decades. In most people, it is quite mild and does not cause significant liver damage. However, in some people, continued inflammation slowly damages the liver, eventually resulting in cirrhosis (severe scarring of the liver), liver failure and sometimes liver cancer. Essential data pertaining to the function of NF-kB, are discussed below in relation to HCV-and HBV-induced chronic hepatitis. These viruses perpetuate liver inflammation, inhibit hepatocyte apoptosis and also inhibit the function of antigen-presenting DC (Thumann et al., 2008; Zimmermann et al., 2008) . The latter effect has a deleterious impact on the adaptive immune response to viral peptides. Both viruses, HCV and HBV, acquired the ability to modify NF-kB function to their own advantage.
Chronic hepatitis C
In chronic hepatitis C, activation of NF-kB is markedly modulated by viral proteins including both core and non-structural proteins, particularly NS5A and NS3. The HCV core protein can promote proliferation of human hepatoma cells by activating NF-kB, thereby leading to TGF-a induction and activation of the ERK/ MAP kinase pathway (Sato et al., 2006) . The region of the core protein responsible for NF-kB activation encompasses amino acids 9-11 which are highly conserved (93%) in all HCV strains (Mann et al., 2006) . NS5A can also activate NF-kB signaling either by inducing degradation of IkBa or through an ER stress response that ultimately results in activation of IKK and NF-kB (Waris et al., 2002 . The NS3 protein is required for viral replication and is responsible for suppressing the body's immune response in chronic hepatitis (Tang et al., 2007) . It has the ability to control innate immune signaling initiated by the cytoplasmic pattern recognition receptors retinoic acid-inducible gene-1 or melanoma differentiation antigen 5 and thereby suppress the downstream activation of IRF-3 and NF-kB through the targeted proteolysis of the adapter protein IPS-1 (Johnson et al., 2007) . Despite this evasive mechanism, persistent HCV infection can result in chronic inflammation. Given the absence of suitable mouse models for studying persistent HCV infections, the exact role of NF-kB in hepatitis C and the effects of IKK and NF-kB inhibition on the progression of this disease can only be determined in primates or human patients.
Chronic hepatitis B
In hepatitis B, the major factor influencing NF-kB function appears to be the HBV protein (HBx), whose gene is conserved among mammalian hepadnaviruses and is essential for viral propagation . Effects of HBx and other viral proteins on NF-kB function during the course of chronic B hepatitis are complex. RelA expression can be induced by HBx and in turn suppress HBx-mediated apoptosis (Diao et al., 2001) . HBx also induces c-Rel expression, which can promote apoptotic cell death in some contexts, and block it in others. One of the HBx to NF-kB signaling pathways is Raf-1-or PKB-mediated (Um et al., 2007) . Integration of HBV into the host genome can occur more often in HCC than in liver cirrhosis. HBx integration into the host genome can alter expression of genes involved in cell cycle and apoptosis, including cyclin A, retinoblastoma protein, Fas-associated death domain protein, TNFR-associated death domain protein and NF-kB family members (Peng et al., 2005) . The HBx protein can therefore affect NFkB activity in more than one way.
Chronic alcoholic hepatitis
Alcoholic hepatitis may occur separately or in combination with cirrhosis. It is a condition characterized by liver cell necrosis and inflammatory reaction. As mentioned above, necrotic hepatocytes release IL-1a and thereby trigger NF-kB activation and inflammation (Sakurai et al., 2008) . Chemokines and cytokines are involved in the pathogenesis of alcoholic hepatitis and are considered to contribute to the migration of leukocytes into the liver during chronic ethanol intoxication, increasing basal H 2 O 2 formation and enhancing activation of NF-kB and AP-1 in Kupffer cells (Bautista, 2002) . Chronic alcoholic hepatitis augments NF-kB activation and proinflammatory cytokine induction (Bautista, 2002) . Complex interactions between NF-kB and other transcription factors, including glucocorticoid receptor (GR) and heat-shock transcription factor, determine the level of activation of immune cells in response to chronic alcohol challenge at the single cell level (Szabo and Mandrekar, 2002) . In endothelial cells, chronic ethanol feeding in a rodent model significantly enhanced MNP-1 binding, but had no effect on NF-kB or AP-1 (Bautista, 2002) . Prolonged alcohol consumption may not only increase chemokine production but at the same time can also suppress the innate immune function of hepatic non-parenchymal cells (Bautista, 2002) . This may be owing to inhibition of NF-kB activity by activated GR or heat-shock transcription factor (Szabo and Mandrekar, 2002) . Another investigation indicated that CD14, a TLR co-receptor present on myeloid cells, has an important function in chronic alcohol-induced liver damage, because chronic ethanol feeding caused more severe liver injury in wild-type mice rather than in CD14 knockout mice (Yin et al., 2001) , supporting the hypothesis that endotoxin acts through CD14 and TLR4 in the development of early alcohol-induced liver injury (Seki et al., 2007) .
NF-jB signaling in liver fibrosis and cirrhosis
Liver fibrosis is the excessive accumulation of extracellular matrix proteins, including collagen, glycoproteins and proteoglycans, that occur in response to most types of chronic liver damage. Advanced liver fibrosis generally results in cirrhosis, liver failure and portal hypertension and often requires liver transplantation. In recent years, the molecular mechanisms underlying liver fibrosis have been clarified. It is not hepatocytes themselves, but activated hepatic stellate cells (HSC), fibroblasts and bone marrow-derived myofibroblast cells that generate collagen leading to derangement of the liver architecture (Iredale et al., 1998) . In these cells, several signaling pathways are reported to have a relationship to extracellular matrix protein production involving NF-kB, c/EBP, AP-1 and other transcription factors (Kiechl et al., 2002) . Many treatments focus on induction of apoptotic death of HSC, the major collagen-producing cell type. If properly induced, the death of these cells may prevent deposition of extracellular matrix and can cause reversal of the fibrotic process. The roles of NF-kB in HSC have been studied for many years. NF-kB is found in activated HSC, where it is involved in upregulating proinflammatory genes encoding cytokines, chemokines and adhesion molecules (Elsharkawy et al., 1999) . NF-kB is involved in protection of HSC from apoptosis which is dependent on transcriptional upregulation of the antiapoptotic proteins TRAF-1, TRAF-2, c-IAP1 and c-IAP2 (Elsharkawy et al., 1999) . Several studies provide indirect evidence of an antiapoptotic role for NF-kB in HSC. IGF-1 induction of HSC apoptosis is associated with downregulation of NF-kB (Saile et al., 2004) , whereas the antiapoptotic effects of TGF-b and TNFa on HSC are associated with increased NF-kB activity (Saile et al., 2001) . Inhibition of NF-kB activity by overexpression of IkB super-repressor reduces the increase in the antiapoptotic protein Bcl-X L induced by TGF-b and TNFa treatment. TGF-b induced apoptosis of HSC is associated with inhibition of NFkB activation and an increased activity of caspase 3 activity (Oakley et al., 2003) .
Development of antihepatic fibrotic drugs and treatments has been based on attenuation of NF-kB activation in HSC. Initial experiments using an adenovirus system to deliver an IkB super-repressor to HSC demonstrated that NF-kB inhibition had no effect on HSC activation or proliferation. It did, however, sensitize the cells to TNFa-induced apoptosis (Lang et al., 2000) . It is worth noting that TNFa is normally antiapoptotic in the absence of NF-kB inhibition. Curcumin can inhibit the proliferation and activation of HSCs, inhibit NF-kB activation, induce the apoptosis of activated HSCs and enhance the activities of MMP-2 and MMP-9-mediated by activation of PPARg signaling (Cheng et al., 2007) . Treatment of both human and rat HSC with sulfasalazine, a known anti-inflammatory drug and potent NF-kB inhibitor, at doses of 0.5 to 2 mM-induced HSC apoptosis as identified by nuclear condensation (Elsharkawy et al., 2005) . The target for the inhibitory activity of sulfasalazine may be IKK (Wahl et al., 1998) . Sulfasalazine, however, is at best a non-selective IKK inhibitor that has the ability to inhibit other kinases, which may also play a regulatory role in HSC apoptosis. Thalidomide at 100-800 nM also inhibited NF-kB transcriptional activity induced by TNFa, and IkBa phosphorylation in the rat HSC cell line HSC-T6, thereby inhibiting the expression of TGF-b1, a-SMA, collagen 1a2, TNFa and iNOS all of which contribute to fibrosis (Chong et al., 2006) . More recent research-however, switches the emphasis in antifibrotic therapy from HSCs to other liver cells. It was reported that an NF-kB decoy can suppress fibrosis and the effect probably results from anti-inflammatory effects in Kupffer cells with only a minor contribution from a direct pro-apoptotic effect on activated HSC (Johnson et al., 2007) . Recent work in human and animal models has shown that liver fibrosis is potentially reversible and, in specific circumstances, demonstrates resolution with a restoration of near normal liver architecture. However, the actual value of anti-NF-kB or anti-IKK therapy remains to be determined, as mice with conditional deletion of IKKg/NEMO knockout in hepatocytes were found to develop spontaneous fibrosis (Luedde et al., 2007) .
NF-jB signaling and hepatocarcinogenesis
The most severe end-result of chronic liver disease is HCC. There have been many studies on the role of NF-kB in the development and progression of HCC (Karin, 2006) . NF-kB activation in both parenchymal (hepatocytes) and non-parenchymal cells of the liver has dramatic effects on the development of HCC, which is one of the major causes of cancer-related deaths. HCC is especially prevalent in parts of Asia and Africa. About 80% of people with HCC have cirrhosis, and chronic infection with the HBV and HCV greatly increases the risk of HCC, which is often diagnosed at an advanced state, when most potentially curative therapies are of limited efficacy. In addition, HCC is highly resistant to available chemotherapeutic agents, which leaves HCC patients with no effective therapeutic options and a poor prognosis.
Persistently elevated levels of NF-kB in the liver because of HBV and HCV infections, bacterial infections and exposure to noxious chemicals contribute to a chronic inflammatory microenvironment that can promote HCC development. As it is shown in Figure 3 , endogenous and exogenous pathogens can induce NF-kB activation in inflammatory cells, thereby leading to secretion of pro-inflammatory cytokines including IL-1b, TNFa, IL-6, VEGF and others, in a manner dependent on IKKb-mediated canonical NF-kB signaling. Of these, IL-6 was shown to have a critical function in HCC development at least in mice (Naugler et al., 2007) . The major role of IL-6 produced by Kupffer cells is to enhance compensatory proliferation of surviving hepatocytes, some of which may harbor oncogenic mutations.
Interestingly, however, IKKb ablation in hepatocytes can enhance the activation of JNK and the expression of c-Jun, which in hepatocytes lead to cyclin D induction and cell cycle entry of hepatocytes (Eferl et al., 2003; Sakurai et al., 2006) . As discussed above, NF-kB is an important modulator of JNK activation in hepatocytes; it is required for prevention of prolonged JNK activation that can lead to hepatocyte death Chang et al., 2006) . By preventing JNK-induced hepatocyte death, NF-kB allows JNK activation to mainly stimulate hepatocyte proliferation. In addition, NF-kB indirectly stimulates hepatocyte proliferation by controlling the transcription of mediators, such as IL-6 in Kupffer cells Naugler et al., 2007) .
The actual contribution of hepatocyte NF-kB activity to hepatocarcinogenesis is even more complex. Firstly, in Mdr2-deficient mice, bile duct inflammation is followed by the appearance of HCC because of prolonged NF-kB activation in hepatocytes (Pikarsky et al., 2004) . In this model TNFa produced by nonparenchymal cells of the liver activates NF-kB in hepatocytes. Blocking NF-kB by transgenic expression of IkBa or by suppressing TNFa-signaling results in the apoptosis of transformed hepatocytes and failure to develop HCC (Pikarsky et al., 2004) . But this effect may be restricted to the late phase of tumor development and applies only to situations where NF-kB is chronically activated.
In another model dependent on administration of the chemical pro-carcinogen DEN liver-specific IKKb knockout mice were found to develop much more HCC than wild-type mice . In these mice, excessive HCC development was linked to increased compensatory proliferation of hepatocytes, which is a direct consequence of the elevated hepatocyte death associated with the absence of IKKb and defective NF-kB activation. Similar findings were recently made in hepatocyte-specific p38a knockout mice which also develop more HCC in response to DEN administration as a result of excessive hepatocyte death and enhanced compensatory proliferation (Sakurai et al., 2008) . In both cases, the necrotic death of hepatocytes was found to result in the release of IL-1a, which then activates MyD88-dependent NF-kB signaling in Kupffer cells, leading to IL-6 induction (Sakurai et al., 2008) . Interference with IKKb activation in Kupffer cells , ablation of IL-6, MyD88 (Naugler et al., 2007) or IL-1 receptor (Sakurai et al., 2008) all interfere with DEN-induced HCC development. The critical function of excessive hepatocyte death in HCC development has been underscored by the specific deletion of IKKg/NEMO in hepatocytes (Luedde et al., 2007) . These mice develop spontaneous liver damage, chronic hepatitis and fibrosis and eventually progress to HCC. This carcinogenic process was shown to be dependent on the hypersensitivity of the IKKg-deficient hepatocytes to oxidative stress and therefore can be prevented by the administration of the antioxidant butylated hydroxyanisole (Luedde et al., 2007) first found to inhibit excessive HCC development in IKKb-liver specific knockout mice . In addition to oxidative stress, the excessive hepatocyte death in both IKKb knockouts (Sakurai et al., 2006) and IKKg knockouts is because of prolonged activation of JNK. Correspondingly, JNK1 Figure 3 The effect of nuclear factor-kappa B (NF-kB) signaling on chronic liver inflammation and hepatocarcinogenesis.
NF-jB signaling, liver disease and hepatoprotective agents B Sun and M Karin ablation prevents HCC development (Sakurai et al., 2006) . Taken together, the studies described above demonstrate a dual role for hepatocyte NF-kB activation in hepatocarcinogenesis. In early stages of tumorigenesis or viral infection, the cytoprotective effect of NF-kB is beneficial because it prevents hepatocyte cell death, and thus avoiding the release of IL-1a by necrotic hepatocytes and the triggering of compensatory proliferation. In late stages of tumorigenesis, however, NF-kB supports malignancy by promoting the survival of the transformed hepatocytes. In nonparenchymal cells of the liver, NF-kB activation during all stages of hepatocarcinogenesis is detrimental because it provides the emerging and growing hepatoma cells with essential growth factors, allowing them to keep on proliferating.
Liver disease treatment: old drugs and new hints
From a molecular perspective, HCC is a heterogeneous type of cancer. In most cases, HCC emerges from a background of persistent liver injury, inflammation and compensatory hepatocyte proliferation, which are characteristic of chronic hepatitis and cirrhosis. Thus chemopreventive agents designed for HCC prevention may work by protecting hepatocytes from death and therefore should not inhibit NF-kB activity. However, inhibition of NF-kB activity may be desired in well developed tumors, as it may be an effective way of sensitizing HCC to chemo-and radio-therapy, which are usually ineffective in this type of cancer. Blockage of NF-kB in hepatocytes can be achieved at different levels of its activation cascade. Many natural or synthetic compounds have been found to inhibit NF-kB activation or transcriptional activity, including selective estrogen receptor modulators, antioxidants and new drugs (proteasome inhibitors, IKKb inhibitors and nucleic acid-based decoys) Table 1 .
Steroids
The major steroids used in immunosuppressive, antiinflammatory and oncolytic therapy are glucocorticoids (GC), such as dexamethasone or prednisolone. The molecular mechanism by which GC mediate their cytotoxic effects is the transactivation and transrepression of specific genes in response activation of GR, a member of the nuclear hormone receptor superfamily. The binding of GC to GR triggers the dissociation of chaperone proteins bound to the unoccupied receptor (heat-shock proteins, BAG-1), thereby exposing the receptor NLS and inducing its translocation to the nucleus. GC-GR dimers can interact with consensus sequences (GREs) in promoter regions of GC-responsive genes, such as c-Myc or GR itself (Yan et al., 2007) . In addition, activated GR can directly interact with AP-1 and NF-kB transcription factors, forming transrepression complexes or induce IkBa expression and retain NF-kB in the cytoplasm (Helmberg et al., 1995) . Both processes, transactivation through GREs and transrepression through interference with AP-1 and NF-kB activities, can contribute to the anti-inflammatory activity of GC and apoptosis of GC-sensitive cells (Tissing et al., 2003) . Although GC are widely used in immunosuppression they do have some limitations when applied for treatment of liver disease, in some cases, the usage of glucocorticoids can lead to liver damage (Vergani and Mieli-Vergani, 2004; Marino et al., 2005) .
Selective estrogen receptor modulators Similar to GCs, ligands for estrogen receptors (ERs) such as estrogen and selective estrogen receptor modulators can also modulate NF-kB activity and might be (Kalaitzidis and Gilmore, 2005) . It was shown that high concentration of the selective estrogen receptor modulators tamoxifen reduces TNFa-induced NF-kB activation in KBM5 and A293 cells through inhibition of IKK activity and the suppression of IkBa degradation while being ER-independent (Takada et al., 2004) . More recently, the SERMs raloxifene and tamoxifen were reported to act as efficient NF-kB inhibitors in multiple myeloma cells (Olivier et al., 2006) . However, neither of these drugs was found to inhibit NF-kB-dependent IL-6 production by KC, which was potently inhibited by estrogen and ERa agonists (Naugler et al., 2007) . Correspondingly, ERa activation prevents hepatocarcinogenesis in DEN-treated male mice (Naugler et al., 2007) . However, it is questionable whether simple ERa agonists can be used to prevent development of HCC in men at high risk for the disease because of their feminizing activity. Future drugs in this class would need to be targeted specifically to Kupffer cells.
Antioxidants Natural antioxidants such as flavanoids, polyphenols, certain vitamins (for example, VHE) and terpenoids have drawn great attention from both the scientific community and the general public, owing to their putative ability to attenuate oxidative stress and thereby suppress cancer development (Khan et al., 2008) . Oxidative stress is caused by a cellular excess of reactive oxygen species and reactive nitrogen species, including superoxides, hydrogen peroxide, hydroxyl radical and peroxynitrite, which can be generated by inflammation or upon loss of natural antioxidants that depend on NF-kB and p38 activation (Sakurai et al., 2008) . Tea polyphenols have antioxidant properties and can be extracted from green, black, or oolong tea (especially green tea). They consist of a series of compounds including: (À)-epigallocatechin-3-gallate, (À)-epigallocatechin, (À)-epicatechin-3-gallate, and (À)-epicatechin. Their therapeutic effects have been validated in the treatment of many cancers, including liver cancer (Chen et al., 2008a) . Administration of green tea was able to prevent an increase in incidence and multiplicities of DEN-induced HCC and also arrest the progression of cholangiocellular tumors in mice (Umemura et al., 2003) . Another polyphenol antioxidant curcumin, a major yellow pigment found in turmeric and derived from the root of the plant Curcuma longa Linn, has been used for centuries in indigenous medicine for the treatment of a variety of inflammatory conditions and other diseases. There is some support for the therapeutic effect of curcumin in liver disease, as it was shown to block hypoxia-stimulated angiogenesis in vitro and downregulate HIF-1a and VEGF expression in vascular endothelial cells (Bae et al., 2006) . Curcumin inhibits DEN-mediated increased expression of oncogenic p21/ WAF1, p53, PCNA, cyclin E and p34 proteins and attenuates NF-kB activation in liver of rats . Another natural pigment synthesized by plants and microorganisms is lycopene. It is categorized as a flavanoid. A recent report suggests lycopene has antimetastatic properties inhibiting the adhesion, invasion and migration of SK-Hep1 human hepatoma cells (Hwang, 2006) . In Wistar rats, lutein and lycopene treatment caused lower numbers of hepatic placental glutathione S-transferase-positive pre-neoplastic lesions in the liver and lower hepatic DNA strand breakage (Toledo et al., 2003) . Other natural antioxidants such as lupeol and pomegranate extracts all have prevention and treatment effects in liver disease (Sunitha et al., 2001) . We believe that with the development of better and synthetic chemistry purification technology the rational design of suitable antioxidant mixtures may find use in the prevention of HCC, cirrhosis and other liver diseases.
Proteasome inhibitors
The proteasome is a multicatalytic proteinase complex responsible for the degradation of most intracellular proteins, including proteins crucial to cell cycle regulation and programmed cell death. Studies of proteasome function were facilitated by the advent of pharmacological proteasome inhibitors, including synthetic peptidyl aldehydes and the bacterial compound lactacystin. These can efficiently block ubiquitin-dependent protein degradation, which is a central metabolic and regulatory process in cell physiology. Through their ability to inhibit IkB degradation, proteasome inhibitors can block NF-kB activation. However, it should be noted that these drugs inhibit many other signaling pathways that depend on proteasomal degradation of key regulatory proteins.
Proteasome inhibitors like bortezomib were found to reduce markers of HSC activation and mediators of fibrosis by repressing NF-kB activation (Anan et al., 2006) . In the lab, the proteasome inhibitor MG132 can induce apoptosis in human hepatoma cells but this was correlated with caspase-dependent cleavage of b-catenin and inhibition of b-catenin-mediated transactivation (Cervello et al., 2004) . Proteasome inhibitors, however, have not proven effective, as yet, in treatment of liver disease treatments and differences exist between the lab and the clinic. Bortezomib appears to be well tolerated in some patients with HCC, because proteasome inhibitors attenuate not only NF-kB signaling, but also other unknown signals (Hegewisch-Becker et al., 2004) . However, other results demonstrated adverse effects and inhibition of proteasome function can induce hepatocyte death by production of massive quantities of proinflammatory chemokines, possibly resulting in neutrophil infiltration, enhanced inflammation and liver injury (Joshi-Barve et al., 2003) . The application of proteasome inhibitors in liver disease certainly needs further evaluation and investigation.
IKK inhibitors
The most critical regulator of NF-kB signaling is the IKK complex and within this complex it is the IKKb subunit that is responsible for activation of the canonical NF-kB pathway in most cell types including hepatocytes (Maeda et al., 2003 . As mentioned above, a variety of 'old' drugs, such as aspirin and sulfasalazin, were found to inhibit IKK catalytic activity. However, new IKK inhibitors that alter assembly of the IKK complex and impede the downstream activation of NF-kB have also been described (Liang et al., 2003; Bernier et al., 2006) . In addition, a cell permeable peptide corresponding to the NEMObinding domain of IKKb is able to block the association of IKKg/NEMO with IKKb and thereby inhibit NF-kB activation (May et al., 2000) . Novel, selective smallmolecule inhibitors of IKKb have also been developed by the pharmaceutical industry. The majority of these compounds interact with the ATP-binding pocket of IKKb. Currently described inhibitors target IKKb kinase activity preferentially, although some may also weakly inhibit IKKa, which is important in controlling the alternative pathway of NF-kB activation . Compared with general proteasome inhibition, IKK inhibitors show more specificity and more controllability. However, under certain circumstances, because of the ability of NF-kB to inhibit IL-1b processing and secretion, these compounds may enhance inflammation (Greten et al., 2007) . Thus we need to learn how to use these inhibitors safely before testing their utility in the treatment of chronic liver disease and even HCC.
Nucleic acid-based treatments
Silencing gene expression through a process known as RNA interference has been known in the plant world for quite some time. It is now apparent that from some in vitro and in vivo models that the prospects for translating this technology into therapeutic applications are robust. Initially, small interfering RNAs (siRNA) or decoy oligonucleotides blocking NF-kB protein synthesis or DNA binding have been developed as experimental tools to study the role of this factor in various disease models. Very few published experiments have described the application of RNA interference to the treatment of liver disease by interference with NF-kB signaling, but RNA interference has already been used as a powerful tool in the treatment of viral hepatitis. It was shown that siRNAs can influence both HBV and HCV infections, by mediating viral RNA degradation and inhibiting viral RNA replication and translation (Trejo-Avila et al., 2007; Chen et al., 2008b) . We recently found that blocking expression of IKKa and IKKb by siRNA can dramatically decrease the proliferation and metastasis of human liver cancer transplanted into mice (unpublished results). These data suggest that such technologies could offer potentially useful therapeutic strategies for targeting NF-kB in the treatment of liver cancer.
Future directions
As discussed above NF-kB and its associated pathways are intricately involved in liver physiology and disease. Selective and even cell type-specific inhibition of NF-kB signaling may offer new ways to treat a variety of liver diseases including cancer. Inhibition may be achieved by targeting either atypical signaling proteins responsible for NF-kB activation in specific types of cells, as well as individual downstream effectors used by NF-kB to achieve some of its numerous effects. Although new inhibitors of NF-kB have recently been developed, clinical experiments evaluating their utility in liver disease are scarce. Undoubtedly, more clinical studies are required to achieve more intimate understanding of distinct roles played by NF-kB signaling in different cell types during the development and progression of different liver pathologies. It is also important to design innovative anticancer therapeutics that allow transient NF-kB inhibition without incurring prohibitive toxicity or loss of innate immunity. Such treatments may allow conventional chemotherapeutics and radiation to become effective in the treatment of HCC.
